EU Hemophilia B Market, Market Segmented by Drug Type (Plasma Derived Coagulation Factor Concentrate, Recombinant Coagulation Factor Concentrates, Desmopressin, Others), by Treatment (On-demand, and Prophylaxis), by End-Users (Hospitals, Homecare, Speciality Centres, Others), by Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) and by Route Of Administration (Oral and Injectable) - Growth, Trends and Forecast, 2019-2028 \n \nPublished Date: Feb, 2021
- Published Date: 2022-12-26
- Report ID: 138170
- Pages: 200
-
Format:
Report Overview
The EU Hemophilia B Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period
Hemophilia B is a bleeding disorder characterized by a lack of blood clotting factor IX. Factor IX is an important coagulation factor that is necessary for blood clotting, and it helps control bleeding. The process of blood clot formation is known as coagulation cascade, which uses clotting factors or coagulation factors. The disorder is caused by inherited X-linked recessive trait, a defected gene located on the X chromosome
Market Drivers
High prevalence of hemophilia B and huge financial investment in research and development activities. In addition, high diagnostic rate and emergence of gene therapy to improve the treatment are some of the impacting factors that drive the market growth
1. EU Hemophilia B Market Overview
A. Market Size
2. EU Hemophilia B Market Growth Drivers.
A. Huge financial investment in research and development activities
B. High diagnostic rate and emergence of gene therapy to improve the treatment
3. EU Hemophilia B Market Segmentation
A. By Drug Type
I. Plasma Derived Coagulation Factor Concentrate
II. Recombinant Coagulation Factor Concentrates
III. Desmopressin
IV. Others
B. By Treatment Type
I. On-demand
II. Prophylaxis
C. By End User
I. Hospitals
II. Homecare
III. Speciality Centres
IV. Others
D. By Distribution Channel
I. Hospital Pharmacy
II. Online Pharmacy
III. Retail Pharmacy
E. By Route Of Administration
I. Oral
II. Injectable
4. EU Hemophilia B Major Market Share
A. Market Analysis, Insights and Forecast by Revenue
5. Competitive Landscape
A. Major Players
B. Products in Pipeline
6. Key Company Profiles..
A. Novo Nordisk, Company overview, Product & Services, Strategies & Financials
B. Pfizer, Company overview, Product & Services, Strategies & Financials
C. Bayer AG, Company overview, Product & Services, Strategies & Financials
7. Healthcare Policies and Regulatory Landscape.
A. Policy Changes and Reimbursement Scenario
8. Factors Driving Market Growth
A. Key Industry Developments
B. Mergers and Acquisitions
9. Potential Growth Opportunities
A. Market Opportunities
B. Future Trends
10. Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
